Courtney Flaherty

Courtney Flaherty joined OncLive as an assistant editor in October 2022. Leveraging an educational background in the life sciences and prior experience conducting interviews in a university setting, she plays a key role in shaping social media strategy, covering live conferences, and producing multimedia content for both print and digital platforms. Email: cflaherty@onclive.com

Articles

Dr Duska on PFS2 Data With Pembrolizumab and Chemoradiotherapy in Cervical Cancer

July 17th 2025

Linda R. Duska, MD, MPH, discusses PFS2 data with pembrolizumab plus chemoradiotherapy in newly diagnosed, high-risk cervical cancer.

Dr Finn on Tiragolumab Plus Atezolizumab and Bevacizumab in HCC

July 17th 2025

Richard S. Finn, MD, discusses the background of the MORPHEUS-Liver trial of tiragolumab plus atezolizumab and bevacizumab in HCC.

FDA’s ODAC Votes Against Risk:Benefit Profiles of Belantamab Mafodotin Combos in R/R Myeloma

July 17th 2025

The FDA’s ODAC voted against the risk/benefit profiles of belantamab mafodotin–based combinations in relapsed/refractory multiple myeloma.

DESTINY-Breast09 Data Spark Debate on Sequencing and Frontline Maintenance Strategies in HER2+ Breast Cancer

July 17th 2025

Laura Huppert, MD, discusses the implications of data with first-line T-DXd plus pertuzumab in HER2-positive metastatic breast cancer.

Dr Eng on Real-World Outcomes in US Patients With KRAS G12C–Mutated CRC

July 16th 2025

Cathy Eng, MD, FACP, FASCO, discusses a real-world study of the effect of KRAS G12C mutations on outcomes in patients with metastatic colorectal cancer.

Dr Thaker on IMNN-001 Plus Neoadjuvant Chemo in Newly Diagnosed Ovarian Cancer

July 16th 2025

Premal H. Thaker, MD, MS, discusses data from a study of IMN-001 plus neoadjuvant chemotherapy in newly diagnosed epithelial ovarian cancer.

CUE-101 Plus Pembrolizumab Yields 50% ORR in HPV+ HNSCC With Low PD-L1 Expression

July 16th 2025

In patients with HPV16-positive HNSCC, CUE-101 plus pembrolizumab generated 2 complete responses and a 12-month overall survival rate of 88%.

FDA Grants Orphan Drug Designation to SH-110 for Oral Suspension in Glioma

July 16th 2025

SH-110 received orphan drug designation from the FDA for the treatment of patients with glioma.

Dr Weinberg on the Implications of Data With BXCL701 Plus Pembrolizumab in mPDAC

July 15th 2025

Benjamin A. Weinberg, MD, FACP, discusses the clinical implications of data with BXCL701 plus pembrolizumab in metastatic pancreatic ductal adenocarcinoma.

Dr Mayadev on a ctDNA Analysis of the CALLA Trial in Cervical Cancer

July 15th 2025

Jyoti Mayadev, MD, discusses the value of ctDNA as a prognostic biomarker for relapse and survival in patients with locally advanced cervical cancer.

Lutetium Lu 177 Vipivotide Tetraxetan Positioned for Earlier Use in mCRPC While Radium-223 Sequencing Requires Further Clarification

July 15th 2025

Qian (Janie) Qin, MD, discusses the current arsenal of radioligand therapies in metastatic castration-resistant prostate cancer.

Dr Jones on the Implications of Data from ASCENT-04 for First-Line PD-L1+ TNBC Management

July 15th 2025

Jade E. Jones, MD, discusses the importance of identifying the most effective first-line treatment regimen for PD-L1–positive TNBC.

Dr Qin on Ongoing Investigations of Radium-223 in mCRPC

July 15th 2025

Qian (Janie) Qin, MD, discusses efforts to elucidate the optimal use of radium 223 plus enzalutamide in metastatic castration-resistant prostate cancer.

Dr Logan on Obe-Cel as a Potential Definitive Treatment in R/R B-ALL

July 15th 2025

Aaron C. Logan, MD, PhD, discusses the potential use of obe-cel as definitive treatment in adult relapsed/refractory B-ALL.

Dr Jordan on Challenges With Drug Development in Adult NF1-Associated PN

July 15th 2025

Justin T. Jordan, MD, MPH, FAAN, discusses treatment challenges and recent progress made with targeted therapies in adult NF1-associated PNs.

Dr Randall on Addressing Disparities in Access to Specialized Sarcoma Care

July 14th 2025

R . Lor Randall, MD, FACS, discusses disparities in global access to care for patients with sarcoma.

Dr Kamdar on Patient Monitoring After Liso-Cel in MCL and Hematologic Malignancies

July 14th 2025

Manali Kamdar, MD, discusses an analysis of the timing of CRS and ICANS among patients with MCL and other hematologic malignancies treated with liso-cel.

FELIX Analysis Highlights Factors Associated With Sustained Remission With Obe-Cel in R/R Acute Lymphoblastic Leukemia

July 14th 2025

Certain factors were associated with sustained remission with obe-cel in acute lymphoblastic leukemia.

Molecular Insights Guide First-Line and Post-Transplant Strategies in AML

July 14th 2025

Hetty E. Carraway, MD, MBA, discusses shifting treatment paradigms in AML from the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference.

Adjuvant Dalpiciclib Plus Endocrine Therapy Improves iDFS in HR+/HER2– Early Breast Cancer

July 14th 2025

Adjuvant dalpiciclib plus endocrine therapy met the iDFS primary end point in the DAWNA-A trial in HR-positive, HER2-negative early breast cancer.

x